ANAPTYSBIO, INC

ANABSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1370053

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$17.2M	$10.3M	$63.2M	$75.0M	$8.0M
Research and Development Expense	—	—	—	$80.0M	$99.3M
Operating Expenses	$181.6M	$125.4M	$120.0M	$98.9M	$115.4M
Operating Income (Loss)	-$164.4M	-$115.2M	-$56.8M	-$23.9M	-$107.4M
Interest Expense	—	—	—	—	$1.0M
Nonoperating Income (Expense)	$788.0K	-$13.5M	-$982.0K	$3.9M	$9.9M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$163.6M	-$128.7M	-$57.8M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$483.8M	$452.4M	$610.4M	$643.1M	$416.6M
Assets, Current	$431.9M	$406.8M	$447.2M	$553.9M	$396.6M
Cash and Cash Equivalents, at Carrying Value	$123.1M	$36.0M	$71.3M	$495.7M	$250.5M
Liabilities, Current	$45.4M	$37.4M	$26.1M	$16.1M	$19.8M
Accounts Payable, Current	$4.0M	$4.7M	$2.8M	$1.7M	$4.2M
Stockholders' Equity Attributable to Parent	$262.1M	$356.4M	$396.7M	$405.0M	$486.4M
Common Stock, Shares, Outstanding	$30.5M	$26.6M	$28.5M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$120.8M	-$73.6M	-$45.9M	-$14.2M	-$69.5M
Net Cash Provided by (Used in) Investing Activities	$144.8M	-$394.8M	$38.8M	$94.5M	$131.4M
Net Cash Provided by (Used in) Financing Activities	-$59.3M	$44.0M	$252.3M	-$879.0K	-$4.5M
Payments to Acquire Property, Plant, and Equipment	$807.0K	$358.0K	$1.4M	$569.0K	$805.0K
Payments for Repurchase of Common Stock	$50.0M	$0.00	$0.00	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)